Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An Open-Label Study of XOMA 358 in Patients with Congenital Hyperinsulinism
2016-001275-80Phase 2Completed
- Sponsor
- XOMA
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ersodetug in hyperinsulinism (HI) and congenital hyperinsulinism (HI), sponsored by XOMA. Primary endpoint: Safety and clinical pharmacology of XOMA 358. Started Apr 2016; status: completed.
02
Drugs
ersodetug
03
Conditions
hyperinsulinism (HI)congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2016-001275-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001275-80.